ABLYNX ANNOUNCES WARRANT EXERCISE
July 24 2017 - 1:02AM
REGULATED INFORMATION
GHENT, Belgium, 24 July 2017 - Ablynx
[Euronext Brussels: ABLX; OTC: ABYLY] today announced, in
conformity with Title II of the Law of 2 May 2007 and the Royal
Decree of 14 February 2008, that an additional 19.833 common shares
have been issued by the Company in exchange for €121.444 as the
result of the exercise of warrants.
As a result of this transaction, Ablynx now has
61.153.032 shares outstanding.
The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights
currently is 2.860.214 which equals the total number of voting
rights that may result from the exercise of these warrants.
Currently 1.000 convertible bonds are outstanding entitling the
holders thereof to 7.733.952 shares of the Company in the
aggregate, upon conversion of such convertible bonds.
About Ablynx
Ablynx is a biopharmaceutical company engaged in
the development of Nanobodies, proprietary therapeutic proteins
based on single-domain antibody fragments, which combine the
advantages of conventional antibody drugs with some of the features
of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the
Company has more than 45 proprietary and partnered programmes in
development in various therapeutic areas including inflammation,
haematology, immuno-oncology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies
including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck &
Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo
Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please
contactAblynx:Dr Edwin MosesCEOt: +32 (0)9
262 00 07m: +32 (0)473 39 50 68e: edwin.moses@ablynx.com
Lies VannesteDirector Investor Relationst: +32 (0)9
262 01 37m: +32 (0)498 05 35 79 e:
lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relationsFTI Consulting:Julia
Phillips, Brett Pollard, Mo Noonant: +44 20 3727 1000e:
ablynx@fticonsulting.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c3353a21-4be4-4b3f-a02b-6d4c644bc25e